1. CDER. FDA. Guidance for Industry. Topical dermatologic corticosteroids: In vivo bioequivalence. June 1995.
https://www.fda.gov/ohrms/dockets/dockets/04p0206/04p-0206-ref0001-08-FDA-Guidance-for-Industry-06-1995-vol3.pdf
. Accessed 22 October 2017.
2. Office of Generic Drugs (OGD), FDA. Draft guidance on acyclovir, Recommended March 2012,
https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm296733.pdf
. Accessed 18 October 2017.
3. Office of Generic Drugs (OGD), FDA. Draft guidance on acyclovir, Recommended December 2014; Revised December 2016
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM428195.pdf
. Accessed 22 October 2017.
4. Office of Generic Drugs (OGD), FDA. Draft guidance on dapsone gel, Recommended Dec 2014; Revised October 2017,
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM428205.pdf
) Accessed 22 October 2017.
5. Office of Generic Drugs (OGD), FDA. Draft guidance on docosanol cream, Recommended Oct 2017, (
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM572999.pdf
) Accessed 22 October 2017.